Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

Idiopathic pulmonary fibrosis (IPF) is a long-lasting, continuously advancing, and irrevocable
interstitial lung disorder with an obscure origin and inadequately comprehended …

Introduction: Fibrosis is an irreversible pathological endpoint in many chronic diseases,
including pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is a progressive and often …

Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs
primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality …

Introduction: Idiopathic pulmonary fibrosis (IPF) is a devastating and relentlessly progressive
lung disorder. Previously, it was thought to be a chronic inflammatory disease; however, it is …

Idiopathic pulmonary fibrosis is a nonmalignant disease, yet it carries a prognosis akin to, or
even worse than, many cancers. Until recently, lung transplantation has been the only …

Use of molecular research techniques in large populations of well-phenotyped patients is
leading to major advances in understanding of IPF. As new treatments for IPF emerge, it is to …

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of idiopathic
interstitial pneumonia. The disease, which occurs primarily in middle-aged and older adults …

Pulmonary fibrosis (PF) encompasses a spectrum of chronic lung diseases that
progressively impact the interstitium, resulting in compromised gas exchange …

This is a time of substantial progress in the evaluation and care of patients with idiopathic
pulmonary fibrosis (IPF). In addition to the approval and widespread availability of the first …